Why Syndax Pharmaceuticals (SNDX) Is Up 9.3% After Revuforj's FDA Nod and NCCN Inclusion

Simply Wall St.11-18

Earlier this month, Syndax Pharmaceuticals reported third quarter results showing a 21% increase in total revenue, fueled by strong uptake of its lead therapy Revuforj after it received FDA approval ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584393656?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-18 16:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584393656","market":"sg","top_or_hot":-1,"title":"Why Syndax Pharmaceuticals (SNDX) Is Up 9.3% After Revuforj's FDA Nod and NCCN Inclusion","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Syndax Pharmaceuticals reported third quarter results showing a 21% increase in total revenue, fueled by strong uptake of its lead therapy Revuforj after it received FDA approval ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-93-after-revuforjs-fda\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Syndax Pharmaceuticals (SNDX) Is Up 9.3% After Revuforj's FDA Nod and NCCN Inclusion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Syndax Pharmaceuticals (SNDX) Is Up 9.3% After Revuforj's FDA Nod and NCCN Inclusion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-18 16:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-93-after-revuforjs-fda><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Syndax Pharmaceuticals reported third quarter results showing a 21% increase in total revenue, fueled by strong uptake of its lead therapy Revuforj after it received FDA approval ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-93-after-revuforjs-fda\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-93-after-revuforjs-fda","article_id":"2584393656","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sndx/syndax-pharmaceuticals/news/why-syndax-pharmaceuticals-sndx-is-up-93-after-revuforjs-fda","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584393656","pubTimestamp":1763454229,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Syndax Pharmaceuticals reported third quarter results showing a 21% increase in total revenue, fueled by strong uptake of its lead therapy Revuforj after it received FDA approval for expanded use and was included in the NCCN guidelines.\nAn interesting insight from this report is that these regulatory and clinical milestones, coupled with robust cash balances and a narrowed net loss, highlight Syndax's advancing operational progress and its strengthened foundation for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"为什么Syndax Pharmaceuticals(SNDX)在Revuforj获得FDA批准和NCCN纳入后上涨9.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1.5},"content_text":"Earlier this month, Syndax Pharmaceuticals reported third quarter results showing a 21% increase in total revenue, fueled by strong uptake of its lead therapy Revuforj after it received FDA approval for expanded use and was included in the NCCN guidelines. An interesting insight from this report is that these regulatory and clinical milestones, coupled with robust cash balances and a narrowed net loss, highlight Syndax's advancing operational progress and its strengthened foundation for future pipeline development. We'll now explore how the broader FDA approval and NCCN inclusion for Revuforj could reshape Syndax's investment narrative and growth outlook. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.AdvertisementSyndax Pharmaceuticals Investment Narrative RecapOwning Syndax Pharmaceuticals shares hinges on confidence in the company’s ability to drive expanding commercial adoption for Revuforj and Niktimvo, especially through successful label expansions in precision oncology. The recent FDA approval of Revuforj for relapsed or refractory AML with an NPM1 mutation and its inclusion in NCCN guidelines directly underpins this near-term catalyst, potentially accelerating uptake, but the central risk of overdependence on these lead assets remains significant and not meaningfully reduced by this news. Among Syndax’s latest milestones, the FDA’s October approval of Revuforj for a broader AML population stands out, aligning closely with the company’s biggest catalyst: broader regulatory wins that could materially expand patient reach and revenues while supporting its growth trajectory. However, in contrast, investors should be aware that any clinical or regulatory setback for Revuforj or Niktimvo could ... Read the full narrative on Syndax Pharmaceuticals (it's free!)Syndax Pharmaceuticals' outlook anticipates $603.4 million in revenue and $43.5 million in earnings by 2028. Achieving this will require 97.8% annual revenue growth and a $378.5 million increase in earnings from the current $-335.0 million.Uncover how Syndax Pharmaceuticals' forecasts yield a $38.85 fair value, a 126% upside to its current price.Exploring Other PerspectivesSNDX Community Fair Values as at Nov 2025 Six members of the Simply Wall St Community pegged Syndax’s fair value estimates between US$9.64 and US$141.86 per share. As you consider the wide spread in these views, remember Syndax’s future growth depends heavily on maintaining momentum for recent regulatory successes, one of several uncertainties to weigh when comparing such diverse opinions.Explore 6 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth over 8x more than the current price!Build Your Own Syndax Pharmaceuticals NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.Searching For A Fresh Perspective?Every day counts. These free picks are already gaining attention. See them before the crowd does:AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 38 best rare earth metal stocks of the very few that mine this essential strategic resource.Uncover the next big thing with financially sound penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584393656","isCrawlerRequest":true}